Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CEO Sean Duffy sold 25,886 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $22.68, for a total transaction of $587,094.48. Following the completion of the transaction, the chief executive officer owned 411,861 shares in the company, valued at $9,341,007.48. This trade represents a 5.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Omada Health Price Performance
Shares of OMDA traded up $0.46 during trading hours on Monday, hitting $22.85. 727,962 shares of the stock were exchanged, compared to its average volume of 1,212,556. The firm has a market capitalization of $1.36 billion and a P/E ratio of -84.63. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The business has a 50-day moving average of $17.32 and a 200-day moving average of $15.09.
Omada Health (NASDAQ:OMDA – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The business had revenue of $78.05 million for the quarter. As a group, analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. Morgan Stanley restated an “overweight” rating and set a $30.00 price target on shares of Omada Health in a report on Monday, June 22nd. JPMorgan Chase & Co. dropped their target price on shares of Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Omada Health in a research note on Friday, May 8th. Weiss Ratings raised shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. Finally, Canaccord Genuity Group set a $24.00 price objective on shares of Omada Health in a report on Friday, May 8th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.91.
Check Out Our Latest Research Report on OMDA
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Stories
- Five stocks we like better than Omada Health
- Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore
- As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
- KBR Insiders Are Buying While the Market Misreads Its Spinoff
- Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
